NPR2 Variants Are Frequent among Children with Familiar Short Stature and Respond Well to Growth Hormone Therapy
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
31990356
DOI
10.1210/clinem/dgaa037
PII: 5716766
Knihovny.cz E-zdroje
- Klíčová slova
- NPR2, familial short stature, growth hormone treatment, growth plate disorders, next-generation sequencing,
- MeSH
- biologické markery analýza MeSH
- dítě MeSH
- dospělí MeSH
- fenotyp MeSH
- jednonukleotidový polymorfismus * MeSH
- kohortové studie MeSH
- kojenec MeSH
- lidé MeSH
- lidský růstový hormon aplikace a dávkování MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nanismus farmakoterapie genetika patologie MeSH
- následné studie MeSH
- předškolní dítě MeSH
- prognóza MeSH
- receptory pro atriální natriuretický faktor genetika MeSH
- tělesná výška účinky léků genetika MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- atrial natriuretic factor receptor B MeSH Prohlížeč
- biologické markery MeSH
- lidský růstový hormon MeSH
- receptory pro atriální natriuretický faktor MeSH
CONTEXT: The C-type natriuretic peptide receptor encoded by the NPR2 gene is a paracrine regulator of the growth plate; heterozygous NPR2 variants cause short stature with possible presence of different signs of bone dysplasia. To date, the effect of growth hormone (GH) treatment has been described in a few individuals with NPR2 gene variants with inconsistent results. OBJECTIVES: To identify NPR2 gene variants among children with familial short stature (FSS) and to describe their phenotype, including GH treatment response. DESIGN, SETTINGS AND PATIENTS: Out of 747 patients with short stature treated with GH in a single center, 87 with FSS met the inclusion criteria (pretreatment height ≤ -2 standard deviation in both the patient and the shorter parent, unknown genetic etiology). Next-generation sequencing methods were performed to search for NPR2 gene variants. The results were evaluated using the American College of Medical Genetics and Genomics guidelines. The GH treatment response (growth velocity improvement and height standard deviation score development over the first 5 years of treatment) was evaluated. RESULTS: In 5/87 children (5.7%), a (likely) pathogenic variant in the NPR2 gene was identified (p.Ile558Thr [in 2], p.Arg205*, p.Arg557His, p.Ser603Thr). Two children had disproportionate short-limbed short stature, 1 a dysplastic 5th finger phalanx. The growth velocity in the first year of GH treatment accelerated by 3.6 to 4.2 cm/year; the height improved by 1.2 to 1.8 SD over 5 years of treatment. CONCLUSIONS: NPR2 gene variants cause FSS in a significant proportion of children. Their GH treatment response is promising. Studies including final height data are necessary to assess the long-term efficacy of this therapy.
Citace poskytuje Crossref.org
Monogenic causes of familial short stature
Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene
Analysis of children with familial short stature: who should be indicated for genetic testing?